Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hadoux J
Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,
Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,
Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hautefeuille V
Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,
Keywords: Patients’ perception of information, Quality of Life, Lanreotide,
Introduction: Appendiceal GCAs (previously Goblet Cell Carcinoids) are composed of cells with secretory phenotypes. Several grading systems to predict behaviour are available (e.g.Tang). The latest WHO 5th edition adopted a grading system similar to colon adenocarcinomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Barriuso J, Nonaka D, Nagaraju R, Shenjere P, Lamarca A,
Keywords: goblet cell adenocarcinomas, tang, who grade,
#2990 Pitfalls in Glucagon-Like Peptide-1 Receptor Imaging
Introduction: Physiological pancreatico-duodenal DOTA-Exendin-4 uptake in the Brunner’s glands of the proximal duodenum occurs in Glucagon-like peptide-1 receptor (GLP-1R) imaging and is a known potential pitfall.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Antwi K
Authors: Antwi K, Hepprich M, Reubi J, Christ E, Wild D,
Keywords: insulinoma, GLP-1R imaging,
#2978 Policy Barriers to Increasing Access to Radioligand Therapy for Neuroendocrine Cancers
Introduction: Radioligand therapy is a relatively new treatment approach used in a small number of neuroendocrine cancers and has been shown to improve overall survival and quality of life. Yet because it uses radioactivity, there are particular barriers to its greater integration into cancer care. As neuroendocrine cancers are rare, it is all the more urgent that these barriers be understood and overcome so that this treatment modality can become available to all patients who may benefit.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Merkel C
Authors: Merkel C, Whicher C, Herrmann K, Jervis N, Ćwikła J,
Keywords: PRRT, peptide receptor radionuclide therapy, radioligand therapy, policy, multidisciplinary care, nuclear medicine, neuroendocrine cancer,